Prevention of Age-associated Cardiac and Vascular Dysfunction Using Avmacol ES

Our local IRB approved clinical studies seeking proof of principle for the hypothesis that SFN can be safely administered to humans at doses sufficient to protect age-associated cardiac dysfunctions. Beneficial effects of SFN-therapy will be assessed by Pre- and post-intervention echocardiography, and exercise endurance at 0 and 24 weeks. Peripheral blood cells from treated and control subjects will be compared for mitochondrial respiratory function, oxidative damage, pro-inflammatory cytokines, and expression of antioxidant \& anti-electrophile genes.

Inclusion Criteria: * Age \> 60 years * Diagnosis of HFpEF (HF symptoms with a normal EF (\>/=50 %) * Ability to walk more than 500 feet (by self-report) * Willing to avoid taking all over the counter antioxidant phytochemical supplements (vegetable or fruit-containing supplement pills) during the study Exclusion Criteria: * Inability to provide informed consent * Diagnosis of active cancer * Inability to read and understand the SF-36 in English * Participants using over the counter antioxidant supplements * Participants with pulmonary or other issues which restrict walking capacity * On oxygen therapy